Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Petru

Showing results (11-20 of 120) with videos related to

Pageof 12
Sort By:
Wiener Klinische Wochenschrift|December 5, 1986
On the relevance of "second-line" cytotoxic chemotherapy in patients with metastatic breast cancer resistant to standard combinationsE Petru, D Schmähl
Deutsche Medizinische Wochenschrift (1946)|May 23, 1986
[Secondary tumors following cytostatic chemotherapy with alkylating agents in man; the toxicological viewpoints]D Schmähl, E Petru
Bailliere'S Clinical Obstetrics and Gynaecology|December 1, 1988
Pelvic and para-aortic lymphadenectomy in cervical cancerR Winter, E Petru, J Haas
Gynakologische Rundschau|January 1, 1989
[Change in obstetrical risk in adolescent primiparous patients--a comparative study]W Walcher, E Petru, G Tscherne
Gynecologic Oncology|October 5, 2001
Possible influence of granulocyte colony-stimulating factor and recombinant human erythropoietin on human chorionic gonadotropin secretion during chemotherapy for choriocarcinomaA Lösch, J Lahodny, E Petru
Gynecologic Oncology|January 22, 2005
Re: "Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy"E Petru, C Petru, Ch Benedicic
Gynakologische Rundschau|January 1, 1991
[Lymph node status in corpus and cervix cancer]F Girardi, E Petru, J Haas
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 13, 2002
Long-term disease-free survival after breast cancer metastatic to the ovaryGerda Zehetleitner, I Thiel, E Petru
Gynecologic Oncology|April 8, 2006
Re: intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group StudyE Petru, Ch Benedicic, A Huell
Journal of Cancer Research and Clinical Oncology|January 1, 1990
Potentiation of cisplatin cytotoxicity by methylxanthines in vitroE Petru, G Boike, B U Sevin
Pageof 12

Showing results (11-20 of 120) with videos related to

Sort By:
Pageof 12
Wiener Klinische Wochenschrift|December 5, 1986
On the relevance of "second-line" cytotoxic chemotherapy in patients with metastatic breast cancer resistant to standard combinationsE Petru, D Schmähl
Deutsche Medizinische Wochenschrift (1946)|May 23, 1986
[Secondary tumors following cytostatic chemotherapy with alkylating agents in man; the toxicological viewpoints]D Schmähl, E Petru
Bailliere'S Clinical Obstetrics and Gynaecology|December 1, 1988
Pelvic and para-aortic lymphadenectomy in cervical cancerR Winter, E Petru, J Haas
Gynakologische Rundschau|January 1, 1989
[Change in obstetrical risk in adolescent primiparous patients--a comparative study]W Walcher, E Petru, G Tscherne
Gynecologic Oncology|October 5, 2001
Possible influence of granulocyte colony-stimulating factor and recombinant human erythropoietin on human chorionic gonadotropin secretion during chemotherapy for choriocarcinomaA Lösch, J Lahodny, E Petru
Gynecologic Oncology|January 22, 2005
Re: "Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy"E Petru, C Petru, Ch Benedicic
Gynakologische Rundschau|January 1, 1991
[Lymph node status in corpus and cervix cancer]F Girardi, E Petru, J Haas
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 13, 2002
Long-term disease-free survival after breast cancer metastatic to the ovaryGerda Zehetleitner, I Thiel, E Petru
Gynecologic Oncology|April 8, 2006
Re: intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group StudyE Petru, Ch Benedicic, A Huell
Journal of Cancer Research and Clinical Oncology|January 1, 1990
Potentiation of cisplatin cytotoxicity by methylxanthines in vitroE Petru, G Boike, B U Sevin
Pageof 12